ArticleGeneral thoracic and cardiovascular surgery2026
Risk factors associated with saphenous vein graft in-stent restenosis.
Article in General thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study examined the risk factors of in-stent restenosis (ISR) group after saphenous vein grafts (SVGs) percutaneous coronary intervention.
methodsFrom March 2007 to February 2021, we collected 385 cases of SVGs percutaneous coronary intervention at the Tehran heart center. Patients experiencing ischemic symptoms were examined during follow-ups by cardiologists, who recommended a second coronary artery angiography. On the basis of coronary artery angiography, the cases were classified as ISR group (n = 284) or non-ISR group (n = 101). The medical history, biochemical indicators, coronary artery lesion features, and stent characteristics were retrospectively evaluated. Using univariate and multivariable Cox regression, risk factors for ISR group have been discovered.
resultsSVG ISR group was verified in 284 of the total number of patients (73.8%). The median length of follow-up was 8.6 years (95% CI = 7.1-10.0 years). Lower body mass index (HR = 0.95, 95% CI = 0.92-0.98, p = 0.006), lower left ventricular ejection fraction (HR = 0.94, 95% CI = 0.91-0.99, p = 0.001), and longer stent length (HR = 1.03, 95% CI = 1.01-1.05, p = 0.002), remained independently associated with ISR group after multivariable analysis.
conclusionLower body mass index, lower left ventricular ejection fraction, and longer stent length are independent predictors of ISR group after SVGs percutaneous coronary intervention.
Indexed as
Identifiers
42217118What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.